EHang to Report Second Quarter 2020 Unaudited Financial Results on Tuesday, August 25, 2020
August 18, 2020 08:30 ET
|
EHang Holdings Limited
GUANGZHOU, China, Aug. 18, 2020 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company” ) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform...
EHang Drives Forward UAM Implementation in Europe
August 14, 2020 09:15 ET
|
EHang Holdings Limited
- UAM pilot city partnership with Linz, Austria - EHang 216 autonomous aerial vehicle to take off in Linz soon VIENNA, Austria, Aug. 14, 2020 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq:...
Freeline Announces Pricing of Initial Public Offering
August 07, 2020 02:49 ET
|
Freeline Therapeutics
LONDON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (“Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the...
Freeline Launches Roadshow for Initial Public Offering
August 03, 2020 06:30 ET
|
Freeline Therapeutics
LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (“Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the...
EHang 216 Obtained Special Flight Operations Certificate from Transport Canada Civil Aviation
July 29, 2020 08:59 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 29, 2020 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (AAV) technology platform company,...
Freeline files registration statement for proposed initial public offering in the United States
July 20, 2020 02:00 ET
|
Freeline Therapeutics
LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of...
Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
July 13, 2020 11:45 ET
|
Freeline Therapeutics
- Updated FLT180a data in the B-AMAZE study in severe Haemophilia B patients demonstrated the potential for sustained normal FIX activity levels - - Additional data were presented in 5 poster...
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
July 09, 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael...
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
July 08, 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
Freeline Closes $120 Million Series C Financing Round
June 30, 2020 02:00 ET
|
Freeline Logo
LONDON, June 30, 2020 (GLOBE NEWSWIRE) -- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million...